IFNAR1: the protein that guards mitochondrial health in Parkinson's disease

IFNAR1 functions as a mitochondrial guardian in the brain, and its loss unleashes a cascade of cellular deterioration that explains how sporadic Parkinson's evolves into dementia. Researchers demonstrated that mice lacking neuronal IFNAR1 develop cortical neurodegeneration, dopaminergic cell loss in the substantia nigra, and Lewy-body-like inclusions—the pathological hallmarks of Parkinson's with dementia—alongside progressive motor and cognitive deficits. The mechanism splits two ways: IFNAR1 absence impairs mitophagy, the cellular cleanup system for damaged mitochondria, while simultaneously triggering glucose hypermetabolism that depletes cellular resources further. Selective loss of IFNAR1 in astrocytes recapitulates neuropsychiatric symptoms, revealing specialized roles depending on cell type. For the biohacker or clinician interested in brain longevity, these findings raise a practical question: can IFNAR1 be restored pharmacologically before symptoms emerge? The answer requires clinical trials, but the mechanism is now solid enough to justify investment in this therapeutic pathway.